{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:13:38Z","timestamp":1793330018957,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The National Key Project for the Four Major Non-Communicable Diseases by the National Health Commission","award":["2025ZD0548100"],"award-info":[{"award-number":["2025ZD0548100"]}]},{"name":"the Shanghai Municipal Health Commission Clinical Research Special Program","award":["202340038"],"award-info":[{"award-number":["202340038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13300-026-01872-6","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:45:59Z","timestamp":1776768359000},"page":"853-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide\u00a01 Receptor Agonists (GLP-1\u00a0RAs)"],"prefix":"10.1007","volume":"17","author":[{"given":"Jiaxun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhou","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1872_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1509561","volume":"16","author":"L He","year":"2025","unstructured":"He L, Li J, Cheng X, Luo L, Huang Y. Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. Front Pharmacol. 2025;16:1509561. https:\/\/doi.org\/10.3389\/fphar.2025.1509561.","journal-title":"Front Pharmacol"},{"key":"1872_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108656","volume":"172","author":"J Li","year":"2021","unstructured":"Li J, He K, Ge J, Li C, Jing Z. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type\u00a02 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;172:108656. https:\/\/doi.org\/10.1016\/j.diabres.2021.108656.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1872_CR3","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045","volume":"77","author":"M Kokkorakis","year":"2025","unstructured":"Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002. https:\/\/doi.org\/10.1124\/pharmrev.123.001045.","journal-title":"Pharmacol Rev"},{"key":"1872_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108824","volume":"269","author":"A Arredouani","year":"2025","unstructured":"Arredouani A. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? Pharmacol Ther. 2025;269:108824. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108824.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1872_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2337\/dc24-1533","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Ghouri N, Misra A, et al. Comparative efficacy of glucagon-like peptide 1 receptor agonists for cardiovascular outcomes in Asian versus White populations: systematic review and meta-analysis of randomized trials of populations with or without type\u00a02 diabetes and\/or overweight or obesity. Diabetes Care. 2025;48(3):489\u201393. https:\/\/doi.org\/10.2337\/dc24-1533.","journal-title":"Diabetes Care"},{"issue":"1","key":"1872_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01489-6","volume":"21","author":"M Husain","year":"2022","unstructured":"Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovasc Diabetol. 2022;21(1):64. https:\/\/doi.org\/10.1186\/s12933-022-01489-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1872_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","volume":"44","author":"JM Yabut","year":"2023","unstructured":"Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023;44(1):14\u201332. https:\/\/doi.org\/10.1210\/endrev\/bnac018.","journal-title":"Endocr Rev"},{"issue":"2","key":"1872_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bcp.15417","volume":"89","author":"Q Lyu","year":"2023","unstructured":"Lyu Q, Ye P, Zhang H, et al. Safety of sugammadex for reversal of neuromuscular block: a postmarketing study based on the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2023;89(2):449\u201357. https:\/\/doi.org\/10.1111\/bcp.15417.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1872_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","volume":"28","author":"CT Ruff","year":"2022","unstructured":"Ruff CT, Baron M, Im K, O\u2019Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type\u00a02 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022;28(1):89\u201395. https:\/\/doi.org\/10.1038\/s41591-021-01584-3.","journal-title":"Nat Med"},{"issue":"10511","key":"1872_CR10","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(25)01774-X","volume":"406","author":"TS Hannon","year":"2025","unstructured":"Hannon TS, Chao LC, Barrientos-P\u00e9rez M, et al. Efficacy and safety of tirzepatide in children and adolescents with type\u00a02 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2025;406(10511):1484\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(25)01774-X.","journal-title":"Lancet"},{"issue":"1","key":"1872_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MAO.0000000000004373","volume":"46","author":"KY Pak","year":"2025","unstructured":"Pak KY, Cutri RM, Nadeem W, et al. GLP-1 receptor agonist induced Eustachian tube dysfunction: database and systematic review of otolaryngologic adverse events. Otol Neurotol. 2025;46(1):19\u201322. https:\/\/doi.org\/10.1097\/MAO.0000000000004373.","journal-title":"Otol Neurotol"},{"issue":"5","key":"1872_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051362","volume":"11","author":"AM Patti","year":"2023","unstructured":"Patti AM, Giglio RV, Allotta A, et al. Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type\u00a02 diabetes. Biomedicines. 2023;11(5):1362. https:\/\/doi.org\/10.3390\/biomedicines11051362.","journal-title":"Biomedicines"},{"issue":"31","key":"1872_CR13","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.2174\/1381612819666131206102255","volume":"20","author":"M Rizzo","year":"2014","unstructured":"Rizzo M, Nikolic D, Banach M, Patti A, Montalto G, Rizvi A. Incretin-based therapies, glucometabolic health and endovascular inflammation. CPD Contin Prof Dev. 2014;20(31):4953\u201360. https:\/\/doi.org\/10.2174\/1381612819666131206102255.","journal-title":"CPD Contin Prof Dev"},{"issue":"3","key":"1872_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13300-022-01217-z","volume":"13","author":"D Nikolic","year":"2022","unstructured":"Nikolic D, Patti AM, Giglio RV, et al. Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type\u00a02 diabetes: a real-world 18-month prospective study. Diabetes Ther. 2022;13(3):453\u201364. https:\/\/doi.org\/10.1007\/s13300-022-01217-z.","journal-title":"Diabetes Ther"},{"issue":"6","key":"1872_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2217\/clp.13.67","volume":"8","author":"C Zhang","year":"2013","unstructured":"Zhang C, Klett EL, Coleman RA. Lipid signals and insulin resistance. Clin Lipidol. 2013;8(6):659\u201367. https:\/\/doi.org\/10.2217\/clp.13.67.","journal-title":"Clin Lipidol"},{"issue":"4","key":"1872_CR16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.gie.2024.12.019","volume":"101","author":"MU Baig","year":"2025","unstructured":"Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis. Gastrointest Endosc. 2025;101(4):762-771.e13. https:\/\/doi.org\/10.1016\/j.gie.2024.12.019.","journal-title":"Gastrointest Endosc"},{"key":"1872_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022;13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789.","journal-title":"Front Endocrinol"},{"issue":"4","key":"1872_CR18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/bcp.16354","volume":"91","author":"J Zhou","year":"2025","unstructured":"Zhou J, Wei Z, Lai W, Liu M, Wu X. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: a pharmacovigilance analysis based on the Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2025;91(4):1272\u201380. https:\/\/doi.org\/10.1111\/bcp.16354.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1872_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02091-3","volume":"26","author":"Q Song","year":"2025","unstructured":"Song Q, Gao S, Tan Y. Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system. J Headache Pain. 2025;26(1):147. https:\/\/doi.org\/10.1186\/s10194-025-02091-3.","journal-title":"J Headache Pain"},{"issue":"1","key":"1872_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-024-04112-8","volume":"88","author":"J Zhou","year":"2024","unstructured":"Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X. Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine. 2024;88(1):80\u201390. https:\/\/doi.org\/10.1007\/s12020-024-04112-8.","journal-title":"Endocrine"},{"key":"1872_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2025.107415","volume":"176","author":"S Breit","year":"2025","unstructured":"Breit S, Hubl D. The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: a systematic review. Psychoneuroendocrinology. 2025;176:107415. https:\/\/doi.org\/10.1016\/j.psyneuen.2025.107415.","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"1872_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02548-w","volume":"24","author":"JM Madsen","year":"2025","unstructured":"Madsen JM, Kjaer AK, L\u00f8nborg JT, et al. Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type\u00a02 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2025;24(1):4. https:\/\/doi.org\/10.1186\/s12933-024-02548-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1872_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","volume":"167","author":"L Wang","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type\u00a02 diabetes. Gastroenterology. 2024;167(4):689\u2013703. https:\/\/doi.org\/10.1053\/j.gastro.2024.04.029.","journal-title":"Gastroenterology"},{"key":"1872_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","volume":"82","author":"A Guirguis","year":"2024","unstructured":"Guirguis A, Chiappini S, Papanti PG, et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol. 2024;82:82\u201391. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.02.003.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1872_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103385","volume":"86","author":"M Wang","year":"2025","unstructured":"Wang M, Chen X, Liu Z, et al. Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. eClinicalMedicine. 2025;86:103385. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103385.","journal-title":"eClinicalMedicine"},{"issue":"10456","key":"1872_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(24)01643-X.","journal-title":"Lancet"},{"issue":"1","key":"1872_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.7570\/jomes22012","volume":"31","author":"HN Jung","year":"2022","unstructured":"Jung HN, Jung CH. The upcoming weekly tides (semaglutide vs. tirzepatide) against obesity: STEP or SURPASS? J Obes Metab Syndr. 2022;31(1):28\u201336. https:\/\/doi.org\/10.7570\/jomes22012.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"1872_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","volume":"106","author":"V Selvarajah","year":"2024","unstructured":"Selvarajah V, Robertson D, Hansen L, et al. A randomized phase\u00a02b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024;106(6):1170\u201380. https:\/\/doi.org\/10.1016\/j.kint.2024.08.023.","journal-title":"Kidney Int"},{"key":"1872_CR29","unstructured":"Uppsala Monitoring Centre (UMC) Guideline for using VigiBase data in studies. https:\/\/who-umc.org\/media\/05kldqpj\/guidelineusingvigibaseinstudies.pdf. Accessed Apr 8, 2026."},{"issue":"6","key":"1872_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type\u00a02 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"6","key":"1872_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type\u00a02 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938\u201346. https:\/\/doi.org\/10.1111\/dom.13979.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1872_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ph19010009","volume":"19","author":"IS Alhomoud","year":"2025","unstructured":"Alhomoud IS, Alamer KA. Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in older adults with type\u00a02 diabetes and cardiometabolic disease. Pharmaceuticals. 2025;19(1):9. https:\/\/doi.org\/10.3390\/ph19010009.","journal-title":"Pharmaceuticals"},{"issue":"11","key":"1872_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102640","volume":"16","author":"H Permana","year":"2022","unstructured":"Permana H, Yanto TA, Hariyanto TI. Efficacy and safety of tirzepatide as novel treatment for type\u00a02 diabetes: a systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr Clin Res Rev. 2022;16(11):102640. https:\/\/doi.org\/10.1016\/j.dsx.2022.102640.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"1","key":"1872_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-025-00251-7","volume":"11","author":"D Tuccinardi","year":"2025","unstructured":"Tuccinardi D, Zilich R, Ponzani P, et al. Real-world prescriptions of GLP-1RAs and SGLT2is in type\u00a02 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis. Cardiovasc Diabetol Endocrinol Rep. 2025;11(1):38. https:\/\/doi.org\/10.1186\/s40842-025-00251-7.","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"issue":"10","key":"1872_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ph14100991","volume":"14","author":"AS Bhagavathula","year":"2021","unstructured":"Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and safety of tirzepatide in patients with type\u00a02 diabetes mellitus: a systematic review and meta-analysis of randomized phase\u00a0II\/III trials. Pharmaceuticals. 2021;14(10):991. https:\/\/doi.org\/10.3390\/ph14100991.","journal-title":"Pharmaceuticals"},{"key":"1872_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1121387","volume":"14","author":"Z Meng","year":"2023","unstructured":"Meng Z, Yang M, Wen H, Zhou S, Xiong C, Wang Y. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable? Front Endocrinol. 2023;14:1121387. https:\/\/doi.org\/10.3389\/fendo.2023.1121387.","journal-title":"Front Endocrinol"},{"key":"1872_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1414268","volume":"15","author":"K Niu","year":"2024","unstructured":"Niu K, Fan M, Gao W, Chen C, Dai G. Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024;15:1414268. https:\/\/doi.org\/10.3389\/fphar.2024.1414268.","journal-title":"Front Pharmacol"},{"key":"1872_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1364110","volume":"15","author":"KA Alenzi","year":"2024","unstructured":"Alenzi KA, Alsuhaibani D, Batarfi B, Alshammari TM. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024;15:1364110. https:\/\/doi.org\/10.3389\/fphar.2024.1364110.","journal-title":"Front Pharmacol"},{"issue":"10454","key":"1872_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3.","journal-title":"Lancet"},{"issue":"5","key":"1872_CR40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","volume":"13","author":"BJ Orandi","year":"2025","unstructured":"Orandi BJ, Chen Y, Li Y, et al. GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol. 2025;13(5):374\u201383. https:\/\/doi.org\/10.1016\/S2213-8587(24)00371-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"1872_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194749","volume":"135","author":"ME Cooper","year":"2025","unstructured":"Cooper ME, van Raalte DH. GLP-1 agonists in the treatment of chronic kidney disease in type\u00a02 diabetes and obesity. J Clin Invest. 2025;135(21):e194749. https:\/\/doi.org\/10.1172\/JCI194749.","journal-title":"J Clin Invest"},{"issue":"6","key":"1872_CR42","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2337\/dc21-1798","volume":"45","author":"M Alatrach","year":"2022","unstructured":"Alatrach M, Agyin C, Solis-Herrera C, et al. Dapagliflozin impairs the suppression of endogenous glucose production in type\u00a02 diabetes following oral glucose. Diabetes Care. 2022;45(6):1372\u201380. https:\/\/doi.org\/10.2337\/dc21-1798.","journal-title":"Diabetes Care"},{"issue":"8","key":"1872_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1872_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1210\/clinem\/dgad438","volume":"109","author":"E Cersosimo","year":"2023","unstructured":"Cersosimo E, Alatrach M, Solis-Herrera C, et al. Emergence of a new glucoregulatory mechanism for glycemic control with dapagliflozin\/exenatide therapy in type\u00a02 diabetes. J Clin Endocrinol Metab. 2023;109(1):161\u201370. https:\/\/doi.org\/10.1210\/clinem\/dgad438.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1872_CR45","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","volume":"84","author":"D Edmonston","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, et al. Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type\u00a02 diabetes. J Am Coll Cardiol. 2024;84(8):696\u2013708. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.016.","journal-title":"J Am Coll Cardiol"},{"key":"1872_CR46","doi-asserted-by":"publisher","first-page":"1330936","DOI":"10.3389\/fendo.2024.1330936","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen W, Cai P, Zou W, Fu Z. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA adverse event reporting system database. Front Endocrinol. 2024;15:1330936. https:\/\/doi.org\/10.3389\/fendo.2024.1330936.","journal-title":"Front Endocrinol"},{"issue":"5","key":"1872_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.02.001","volume":"7","author":"H Gonzalez Dorta","year":"2025","unstructured":"Gonzalez Dorta H, Verbeeck J, Crevecoeur J, et al. Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study. Lancet Digit Health. 2025;7(5):100861. https:\/\/doi.org\/10.1016\/j.landig.2025.02.001.","journal-title":"Lancet Digit Health"},{"issue":"8","key":"1872_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327","volume":"8","author":"L Wang","year":"2025","unstructured":"Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type\u00a02 diabetes. JAMA Netw Open. 2025;8(8):e2526327. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26327.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1872_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"key":"1872_CR50","unstructured":"Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type\u00a02 diabetes: a systematic review and meta-analysis. https:\/\/pubmed.ncbi.nlm.nih.gov\/38905435\/. Accessed Nov 7, 2025."},{"key":"1872_CR51","unstructured":"Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors. https:\/\/pubmed.ncbi.nlm.nih.gov\/38470137\/. Accessed Nov 7, 2025."},{"issue":"9","key":"1872_CR52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45181","volume":"15","author":"J Mizumoto","year":"2023","unstructured":"Mizumoto J. Tirzepatide-induced injection site reaction. Cureus. 2023;15(9):e45181. https:\/\/doi.org\/10.7759\/cureus.45181.","journal-title":"Cureus"},{"issue":"9","key":"1872_CR53","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S2213-8587(25)00141-X","volume":"13","author":"L Ji","year":"2025","unstructured":"Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Diabetes Endocrinol. 2025;13(9):777\u201389. https:\/\/doi.org\/10.1016\/S2213-8587(25)00141-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1872_CR54","unstructured":"Navigating medical device safety: current status, challenges, and future regulatory directions. https:\/\/pubmed.ncbi.nlm.nih.gov\/40833550\/. Accessed Nov 7, 2025."},{"issue":"3","key":"1872_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s43588-024-00748-8","volume":"5","author":"D Yan","year":"2025","unstructured":"Yan D, Bao S, Zhang Z, Sun J, Zhou M. Leveraging pharmacovigilance data to predict population-scale toxicity profiles of checkpoint inhibitor immunotherapy. Nat Comput Sci. 2025;5(3):207\u201320. https:\/\/doi.org\/10.1038\/s43588-024-00748-8.","journal-title":"Nat Comput Sci"},{"key":"1872_CR56","unstructured":"Applying AI to structured real-world data for pharmacovigilance purposes: scoping review. https:\/\/pubmed.ncbi.nlm.nih.gov\/39753222\/. Accessed Nov 7, 2025."},{"issue":"1","key":"1872_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01826-5","volume":"8","author":"S Wittlinger","year":"2025","unstructured":"Wittlinger S, Wiest IC, Ladani MJ, et al. How machine learning on real world clinical data improves adverse event recording for endoscopy. NPJ Digit Med. 2025;8(1):424. https:\/\/doi.org\/10.1038\/s41746-025-01826-5.","journal-title":"NPJ Digit Med"},{"key":"1872_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2024.12.019","author":"MU Baig","year":"2024","unstructured":"Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis. Gastrointest Endosc. 2024. https:\/\/doi.org\/10.1016\/j.gie.2024.12.019.","journal-title":"Gastrointest Endosc"},{"key":"1872_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1503713","volume":"15","author":"Y Hua","year":"2024","unstructured":"Hua Y, Li N, Lao J, Chen Z, Ma S, Li X. Machine learning models for coagulation dysfunction risk in inpatients administered \u03b2-lactam antibiotics. Front Pharmacol. 2024;15:1503713. https:\/\/doi.org\/10.3389\/fphar.2024.1503713.","journal-title":"Front Pharmacol"},{"key":"1872_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.117860","volume":"325","author":"J Wei","year":"2024","unstructured":"Wei J, Dai J, Sun Y, Meng Z, Ma H, Zhou Y. TIRPnet: risk prediction of traditional Chinese medicine ingredients based on a deep neural network. J Ethnopharmacol. 2024;325:117860. https:\/\/doi.org\/10.1016\/j.jep.2024.117860.","journal-title":"J Ethnopharmacol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01872-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:23:01Z","timestamp":1781079781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01872-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1872"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01872-6","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest among the authors. Jiaxun Li, Jizhou Liang, Wei Zhang, Jia He and Xiaofei Ye have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data used in this study have been anonymized by the VigiBase database and no ethical approval is required. According to the \u201cGuideline for using VigiBase data in studies\u201d [\n                      \n                      ], reports sent from the WHO PIDM member countries to VigiBase are anonymized. Personal information is currently not available in the public level of VigiBase data. Therefore, ethics approval and informed consent were not required. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}